Tandem Diabetes Care Reports Rapid Uptake and High Satisfaction Scores For t:slim X2 Insulin Pump Remote Software Update Following Launch of CGM Integration
"We are demonstrating our continued commitment to customer care by
providing a simple, efficient and cost-effective way for people to keep
up with our latest technology," said
"Tandem has brought diabetes technology into the future with their
Tandem Device Updater," said Dr.
To learn more about the t:slim X2 Insulin Pump and its remote
software update capability, visit www.tandemdiabetes.com/tslimX2
or call (877) 801-6901, Monday - Friday
Download Tandem's free t:simulator™ App to experience the touchscreen interface of the t:slim X2 Pump with Dexcom G5 Mobile CGM integration directly on your mobile device. For more information and to download the app, visit http://www.tandemdiabetes.com/tsimulator.
Information for Current t:slim X2 Pump Users
All eligible t:slim X2 Pump users have the option to add Dexcom G5 Mobile CGM integration via a software update using a personal computer.1 Individual emails have been sent directly to t:slim X2 Pump customers with instructions on how to perform the update and their unique Update ID number. The software update is Mac® and PC compatible. For more information on system requirements, visit www.tandemdiabetes.com/updater.
Remote Software Updates for Insulin Pumps
Tandem is the only company with a tool for providing remote software updates for its insulin pumps using a personal computer. The power of the t:slim X2 Pump's touchscreen allows for buttons to be moved and data like the interactive CGM screen to be added via software updates without getting a new device. With innovations in diabetes technology consistently moving faster than the typical insurance pump replacement cycle, remote software updates make it easier to make a purchasing decision today without worrying that the device will soon be outdated. Future Tandem products are being developed with software updates in mind, with the goal of delivering new technologies to both new and current customers at the same time.2
Forward Looking Statement
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding the Company's ability to develop and deploy future software updates and deliver new technologies to both new and current customers at the same time. The Company's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including the Company's ability to complete the development of automated insulin delivery algorithms for the t:slim X2, the Company's ability to successfully complete clinical trials for new products when anticipated (or at all), the potential that the results of any such clinical trials may not be sufficient to support regulatory approvals for new products as anticipated and the Company's ability to obtain regulatory approvals for future products and product features generally. Other risks and uncertainties are identified in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other documents that the Company files with the
1 Dexcom G5 Mobile CGM sold separately. CGM coverage may vary
based on insurance. Please consult your CGM supplier for coverage
2 Additional feature updates are not currently available for the t:slim X2 Pump with Dexcom G5 CGM integration and are subject to future
News Provided by Acquire Media